Correction to: Augmentation of tumor expression of HLADR, CXCL9, and CXCL10 may improve olfactory neuroblastoma immunotherapeutic responses

Affiliations

• ¹ Sinonasal and Skull Base Tumor Program, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ² University of Miami Miller School of Medicine, Miami, MD, USA.
• ³ Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁴ Section on Translational Tumor Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁵ Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
• ⁶ Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
• ⁷ Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
• ⁸ Sinonasal and Skull Base Tumor Program, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. nyall.london@nih.gov.
• ⁹ Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. nyall.london@nih.gov.
• ¹⁰ Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. nyall.london@nih.gov.